EUROPEAN JOURNAL OF HEART FAILURE, cilt.18, sa.9, ss.1193-1202, 2016 (SCI İndekslerine Giren Dergi)
AimsTo assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection fraction 35%).